Lead, genetic susceptibility, and risk of adult brain tumors

Preetha Rajaraman, Patricia A. Stewart, Jonathan M. Samet, Brian S Schwartz, Martha S. Linet, Shelia Hoar Zahm, Nathaniel Rothman, Meredith Yeager, Howard A. Fine, Peter M. Black, Jay Loeffler, William R. Shapiro, Robert G. Selker, Peter D. Inskip

Research output: Contribution to journalArticle

Abstract

Background: Although few etiologic factors for brain tumors have been identified, limited data suggest that lead may increase the risk of brain tumors, particularly meningioma. The ALAD G177C polymorphism affects the toxicokinetics of lead and may confer genetic susceptibility to adverse effects of lead exposure. Methods: We examined occupational exposure to lead and risk of brain tumors in a multisite, hospital-based, case-control study of 489 patients with glioma, 197 with meningioma, and 799 non-cancer controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to hospital. ALAD genotype was assessed by a Taqman assay for 355 glioma patients, 151 meningioma patients, and 505 controls. Exposure to lead was estimated using a rigorous questionnaire-based exposure assessment strategy incorporating lead measurement and other occupational data abstracted from published articles and reports. Results: Increased risk of meningioma with occupational lead exposure (estimated by odds ratios and 95% confidence intervals) was most apparent in individuals with the ALAD2 variant allele, for whom risk increased from 1.1 (0.3-4.5) to 5.6 (0.7-45.5) and 12.8 (1.4-120.8) for estimated cumulative lead exposures of 1 to 49 μg/m3-y, 50 to 99 μg/m3-y, and ≥100 μg/m3-y, respectively, compared with unexposed individuals (two-sided P trend = 0.06). This relationship became stronger after excluding occupational lead exposures characterized by a low confidence level or occurring in the 10 years before meningioma diagnosis. Occupational lead exposure was not associated with glioma risk. Conclusions: Although our results indicate that lead may be implicated in meningioma risk in genetically susceptible individuals, these results need to be interpreted with caution given the small numbers of exposed cases with a variant genotype.

Original languageEnglish (US)
Pages (from-to)2514-2520
Number of pages7
JournalCancer Epidemiology Biomarkers and Prevention
Volume15
Issue number12
DOIs
StatePublished - Dec 2006

Fingerprint

Genetic Predisposition to Disease
Brain Neoplasms
Meningioma
Occupational Exposure
Glioma
Genotype
Lead
Case-Control Studies
Alleles
Odds Ratio
Confidence Intervals

ASJC Scopus subject areas

  • Epidemiology
  • Oncology

Cite this

Rajaraman, P., Stewart, P. A., Samet, J. M., Schwartz, B. S., Linet, M. S., Zahm, S. H., ... Inskip, P. D. (2006). Lead, genetic susceptibility, and risk of adult brain tumors. Cancer Epidemiology Biomarkers and Prevention, 15(12), 2514-2520. https://doi.org/10.1158/1055-9965.EPI-06-0482

Lead, genetic susceptibility, and risk of adult brain tumors. / Rajaraman, Preetha; Stewart, Patricia A.; Samet, Jonathan M.; Schwartz, Brian S; Linet, Martha S.; Zahm, Shelia Hoar; Rothman, Nathaniel; Yeager, Meredith; Fine, Howard A.; Black, Peter M.; Loeffler, Jay; Shapiro, William R.; Selker, Robert G.; Inskip, Peter D.

In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 12, 12.2006, p. 2514-2520.

Research output: Contribution to journalArticle

Rajaraman, P, Stewart, PA, Samet, JM, Schwartz, BS, Linet, MS, Zahm, SH, Rothman, N, Yeager, M, Fine, HA, Black, PM, Loeffler, J, Shapiro, WR, Selker, RG & Inskip, PD 2006, 'Lead, genetic susceptibility, and risk of adult brain tumors', Cancer Epidemiology Biomarkers and Prevention, vol. 15, no. 12, pp. 2514-2520. https://doi.org/10.1158/1055-9965.EPI-06-0482
Rajaraman, Preetha ; Stewart, Patricia A. ; Samet, Jonathan M. ; Schwartz, Brian S ; Linet, Martha S. ; Zahm, Shelia Hoar ; Rothman, Nathaniel ; Yeager, Meredith ; Fine, Howard A. ; Black, Peter M. ; Loeffler, Jay ; Shapiro, William R. ; Selker, Robert G. ; Inskip, Peter D. / Lead, genetic susceptibility, and risk of adult brain tumors. In: Cancer Epidemiology Biomarkers and Prevention. 2006 ; Vol. 15, No. 12. pp. 2514-2520.
@article{aaebe74110d246998ec1699a90f2fbe6,
title = "Lead, genetic susceptibility, and risk of adult brain tumors",
abstract = "Background: Although few etiologic factors for brain tumors have been identified, limited data suggest that lead may increase the risk of brain tumors, particularly meningioma. The ALAD G177C polymorphism affects the toxicokinetics of lead and may confer genetic susceptibility to adverse effects of lead exposure. Methods: We examined occupational exposure to lead and risk of brain tumors in a multisite, hospital-based, case-control study of 489 patients with glioma, 197 with meningioma, and 799 non-cancer controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to hospital. ALAD genotype was assessed by a Taqman assay for 355 glioma patients, 151 meningioma patients, and 505 controls. Exposure to lead was estimated using a rigorous questionnaire-based exposure assessment strategy incorporating lead measurement and other occupational data abstracted from published articles and reports. Results: Increased risk of meningioma with occupational lead exposure (estimated by odds ratios and 95{\%} confidence intervals) was most apparent in individuals with the ALAD2 variant allele, for whom risk increased from 1.1 (0.3-4.5) to 5.6 (0.7-45.5) and 12.8 (1.4-120.8) for estimated cumulative lead exposures of 1 to 49 μg/m3-y, 50 to 99 μg/m3-y, and ≥100 μg/m3-y, respectively, compared with unexposed individuals (two-sided P trend = 0.06). This relationship became stronger after excluding occupational lead exposures characterized by a low confidence level or occurring in the 10 years before meningioma diagnosis. Occupational lead exposure was not associated with glioma risk. Conclusions: Although our results indicate that lead may be implicated in meningioma risk in genetically susceptible individuals, these results need to be interpreted with caution given the small numbers of exposed cases with a variant genotype.",
author = "Preetha Rajaraman and Stewart, {Patricia A.} and Samet, {Jonathan M.} and Schwartz, {Brian S} and Linet, {Martha S.} and Zahm, {Shelia Hoar} and Nathaniel Rothman and Meredith Yeager and Fine, {Howard A.} and Black, {Peter M.} and Jay Loeffler and Shapiro, {William R.} and Selker, {Robert G.} and Inskip, {Peter D.}",
year = "2006",
month = "12",
doi = "10.1158/1055-9965.EPI-06-0482",
language = "English (US)",
volume = "15",
pages = "2514--2520",
journal = "Cancer Epidemiology Biomarkers and Prevention",
issn = "1055-9965",
publisher = "American Association for Cancer Research Inc.",
number = "12",

}

TY - JOUR

T1 - Lead, genetic susceptibility, and risk of adult brain tumors

AU - Rajaraman, Preetha

AU - Stewart, Patricia A.

AU - Samet, Jonathan M.

AU - Schwartz, Brian S

AU - Linet, Martha S.

AU - Zahm, Shelia Hoar

AU - Rothman, Nathaniel

AU - Yeager, Meredith

AU - Fine, Howard A.

AU - Black, Peter M.

AU - Loeffler, Jay

AU - Shapiro, William R.

AU - Selker, Robert G.

AU - Inskip, Peter D.

PY - 2006/12

Y1 - 2006/12

N2 - Background: Although few etiologic factors for brain tumors have been identified, limited data suggest that lead may increase the risk of brain tumors, particularly meningioma. The ALAD G177C polymorphism affects the toxicokinetics of lead and may confer genetic susceptibility to adverse effects of lead exposure. Methods: We examined occupational exposure to lead and risk of brain tumors in a multisite, hospital-based, case-control study of 489 patients with glioma, 197 with meningioma, and 799 non-cancer controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to hospital. ALAD genotype was assessed by a Taqman assay for 355 glioma patients, 151 meningioma patients, and 505 controls. Exposure to lead was estimated using a rigorous questionnaire-based exposure assessment strategy incorporating lead measurement and other occupational data abstracted from published articles and reports. Results: Increased risk of meningioma with occupational lead exposure (estimated by odds ratios and 95% confidence intervals) was most apparent in individuals with the ALAD2 variant allele, for whom risk increased from 1.1 (0.3-4.5) to 5.6 (0.7-45.5) and 12.8 (1.4-120.8) for estimated cumulative lead exposures of 1 to 49 μg/m3-y, 50 to 99 μg/m3-y, and ≥100 μg/m3-y, respectively, compared with unexposed individuals (two-sided P trend = 0.06). This relationship became stronger after excluding occupational lead exposures characterized by a low confidence level or occurring in the 10 years before meningioma diagnosis. Occupational lead exposure was not associated with glioma risk. Conclusions: Although our results indicate that lead may be implicated in meningioma risk in genetically susceptible individuals, these results need to be interpreted with caution given the small numbers of exposed cases with a variant genotype.

AB - Background: Although few etiologic factors for brain tumors have been identified, limited data suggest that lead may increase the risk of brain tumors, particularly meningioma. The ALAD G177C polymorphism affects the toxicokinetics of lead and may confer genetic susceptibility to adverse effects of lead exposure. Methods: We examined occupational exposure to lead and risk of brain tumors in a multisite, hospital-based, case-control study of 489 patients with glioma, 197 with meningioma, and 799 non-cancer controls frequency matched on hospital, age, sex, race/ethnicity, and residential proximity to hospital. ALAD genotype was assessed by a Taqman assay for 355 glioma patients, 151 meningioma patients, and 505 controls. Exposure to lead was estimated using a rigorous questionnaire-based exposure assessment strategy incorporating lead measurement and other occupational data abstracted from published articles and reports. Results: Increased risk of meningioma with occupational lead exposure (estimated by odds ratios and 95% confidence intervals) was most apparent in individuals with the ALAD2 variant allele, for whom risk increased from 1.1 (0.3-4.5) to 5.6 (0.7-45.5) and 12.8 (1.4-120.8) for estimated cumulative lead exposures of 1 to 49 μg/m3-y, 50 to 99 μg/m3-y, and ≥100 μg/m3-y, respectively, compared with unexposed individuals (two-sided P trend = 0.06). This relationship became stronger after excluding occupational lead exposures characterized by a low confidence level or occurring in the 10 years before meningioma diagnosis. Occupational lead exposure was not associated with glioma risk. Conclusions: Although our results indicate that lead may be implicated in meningioma risk in genetically susceptible individuals, these results need to be interpreted with caution given the small numbers of exposed cases with a variant genotype.

UR - http://www.scopus.com/inward/record.url?scp=33845973329&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845973329&partnerID=8YFLogxK

U2 - 10.1158/1055-9965.EPI-06-0482

DO - 10.1158/1055-9965.EPI-06-0482

M3 - Article

C2 - 17164378

AN - SCOPUS:33845973329

VL - 15

SP - 2514

EP - 2520

JO - Cancer Epidemiology Biomarkers and Prevention

JF - Cancer Epidemiology Biomarkers and Prevention

SN - 1055-9965

IS - 12

ER -